Innovative Paper-Based Device Detects Immune Defects in Just 10 Minutes with High Precision

A novel paper-based diagnostic device rapidly detects harmful autoantibodies associated with immune deficiencies in just 10 minutes, offering high sensitivity and clinical accuracy for quick on-site testing.
Researchers at National Taiwan University have introduced a groundbreaking, low-cost diagnostic tool that rapidly identifies immune deficiencies caused by harmful autoantibodies. This innovative paper-based device targets anti-interferon-γ autoantibodies, which can compromise the immune system and make patients susceptible to persistent and severe infections. The device features a sophisticated 3D folded paper structure combined with gold nanoparticle signal amplification, allowing for automated and one-step testing using only a small sample of blood serum. Results are delivered in approximately 10 minutes, representing a tenfold improvement in sensitivity over traditional methods.
This rapid and straightforward approach utilizes preloaded reagents in layered compartments, eliminating the need for complex laboratory equipment. Clinical validation has demonstrated the device's remarkable accuracy, achieving 100% sensitivity and specificity, thus ensuring reliable detection of these autoantibodies in patients.
The portable and user-friendly nature of this test makes it especially suitable for use in various healthcare settings, including remote clinics and emergency situations. By enabling quick diagnosis, it can significantly guide treatment strategies and monitor patient recovery more effectively.
The development aims to provide accessible, highly sensitive, on-site diagnostic solutions that can improve early detection and management of immune-related conditions without relying on expensive laboratory infrastructure. The study detailing this innovation is published in Biosensors and Bioelectronics.
For more information, visit the original research link: https://linkinghub.elsevier.com/retrieve/pii/S0956566325005986
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
US Suspends Approval of Chikungunya Vaccine Ixchiq Due to Serious Side Effects
The FDA has suspended the approval of the chikungunya vaccine Ixchiq after reports of serious adverse effects, raising concerns about vaccine safety amidst ongoing outbreaks.



